Despite preclinical studiesdemonstrating the anti-inflammatory potential of PAD4 inhibitors and MK blockers,the clinical translation of these compounds remains hindered by obstacles, suchas the high heterogeneity of myocarditis and recruitment difficulties for trialsof rare diseases. The gene discussed is PADI4; the disease is myocarditis.